Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10517-10524

  Wehbe, Hania ^a   Henson, Roger ^a   Meng, Fanyin ^a   Mize Berge, Janna ^a   Patel, Tushar ^a,b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AGAR; CYTOSINE DERIVATIVE; EPIDERMAL GROWTH FACTOR DERIVATIVE; INTERLEUKIN 6;

ARTICLE; AUTOCRINE EFFECT; BILE DUCT CARCINOMA; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

5-METHYLCYTOSINE; AZACITIDINE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DNA METHYLATION; HUMANS; INTERLEUKIN-6; PROMOTER REGIONS (GENETICS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33751280992     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2130     Document Type: Article

References (35)

1. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42.
2. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-33.
3. Yokomuro S, Tsuji H, Lunz JG, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 2000;32:26-35.
4. Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005;42:1329-38.
5. Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T. Translational regulation of x-linked inhibitor of apoptosis protein by interleukin-6: a novel mechanism of tumor cell survival. Cancer Res 2004;64:1293-8.
6. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998;227: 398-404.
7. Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 2006;44:1055-65.
8. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994;9:462-7.
9. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in Cholangiocarcinoma. J Hepatol 2002;37: 633-9.
10. Lee S, Kim WH, Jung HY, Yang MH, Kang GH. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161: 1015-22.
11. Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624-31.
12. Limpaiboon T, Khaenam P, Chinnasri P, et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett 2005;217:213-9.
13. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005;18:412-20.
14. Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL. Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 2001;276:39508-11.
15. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005;2 Suppl 1:S4-11.
16. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004;6:361-71.
17. Marienfeld C, Tadlock L, Yamagiwa Y, Patel T. Inhibition of cholangiocarcinoma growth by tannic acid. Hepatology 2003;37:1097-104.
18. Tadlock L, Patel T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology 2001;33:43-51.
19. Ke N, Albers A, Claassen G, et al. One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 2004;36:826-3.
20. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 2002;31:19-20.
21. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003;4:R7.
22. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O, Majumdar AP. Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol 2004;287:G541-6.
23. Meng F, Yamagiwa Y, Taffetani S, Han J, Patel T. IL-6 activates serum and glucocorticoid kinase via p38α mitogen-activated protein kinase pathway. Am J Physiol Cell Physiol 2005;289:C971-81.
24. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF-α-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003;285:G31-6.
25. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004;41:808-14.
26. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
27. Hodge DR, Peng B, Cherry JC, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005;65: 4673-82.
28. Peng B, Hodge DR, Thomas SB, et al. Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells. J Biol Chem 2005;280:4182-7.
29. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122:985-93.
30. Chiorean MV, Guicciardi ME, Yoon JH, Bronk SF, Kaufmann SH, Gores GJ. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int 2004;24:687-95.
31. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
32. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
33. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
34. Paz MF, Wei S, Cigudosa JC, et al. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet 2003;12:2209-19.
35. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present, and future. Nat Rev Drug Discov 2006;5:37-50.